Navigation Links
Life Technologies Launches 7500 Fast Dx Real-Time PCR Instrument and 3500 Dx Series Genetic Analyzer in Japan
Date:5/10/2011

CARLSBAD, Calif., May 10, 2011 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE), today announced that its 7500 Fast Dx Real-Time PCR Instrument and 3500 Dx Series Genetic Analyzer are now available platforms suitable for in vitro diagnostics (IVD) use in Japan.  Both the 7500 Dx and 3500 Dx were filed as diagnostic application instruments to the Tokyo Metropolitan Government in March.  The approval of these real time PCR and sequencing systems as bona fide diagnostics platforms is a demonstration of Life Technologies' recent approval by the Tokyo Government to operate as a medical company or Market Authorization Holder (MAH) within Japan.

With the 7500 Fast Dx system, clinical laboratories and institutions in Japan that develop in vitro molecular diagnostic assays in oncology, genetic disease and infectious disease, will now be able to leverage the instrument's regulatory clearance to develop tests for clinical applications.  Similarly, the 3500 Dx Series Genetic Analyzer is the first CE IVD- marked capillary electrophoresis system for nucleic acid analysis.  It is intended for use in the analysis of human DNA or RNA for the detection of genetic changes that may lead to disease presence or susceptibility.  

The 7500 enables labs to complete real-time PCR amplification and accurately and precisely quantify nucleic acids in less than 40 minutes.  The instrument's software suite includes customizable security settings, and versatile security, auditing, and e-signature applications that allow users to record all instrument operations, supporting requirements of clinical laboratories to work in a secure environment.  

The 3500 Dx Series enables scientists to run up to 1,100 sequencing or 1,200 genotyping samples per day.  It features a novel consumables design that incorporates the ability to track key information with radio frequency identification (RFID) tags, new optical and thermal sub-systems, and redesigned data collection and analysis software, creating a more cost-effective method for high-quality data analyses.

"Life Technologies Japan is pleased to introduce these diagnostics platforms combining best-in-class technologies with easy-to-use, clinically-compliant interfaces," said Joydeep Goswami, Head of Life Technologies Japan. "These devices will enable physicians and laboratories to rapidly develop new clinical and diagnostic assays using a platform they are familiar with.  We will work closely with the developers of these assays to assist them in bringing their assays to patients quickly and safely."

"Having these market-leading platforms available for IVD assay development significantly broadens the options for molecular diagnostic companies in Japan," adds Michael Paumen, Director at Life Technologies Japan.  "Our flexible partnership programs will appeal to a wide variety of needs."

The 7500 Dx and 3500 Dx platforms are already widely available in many countries in Asia, North America and Europe.

About Life Technologies

Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition.  Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better.  Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics.  The company manufactures both molecular diagnostic and research use only products.  Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products.  Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses.  For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.  Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Patty Zamora
760-476-7818
patty.zamora@lifetech.com


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
2. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
3. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
4. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
5. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
6. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
7. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
8. Senesco Technologies Initiates Preclinical Studies for Cancer Target
9. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
10. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
11. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, the ... unveiled a new store design to enhance the ... healthier food, health-focused products and expanded beauty selections ... help customers discover new offerings. Together with its ... evolution of the customer experience at CVS Pharmacy.  ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
(Date:4/19/2017)... Cardiology devices segment is anticipated to reach the highest market ... segment is likely to create absolute $ opportunity of a ... By the end of 2027, Cardiology Devices segment is projected ... expanding at a CAGR of 18.4% over the forecast period. ... reprocessed medical devices market in terms of revenue ...
Breaking Medicine Technology:
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t tell” applies perfectly ... in the company’s esteemed VISION House demonstration project series. Manifesting the concept of right-sized ... resources they need to live affordably and abundantly without unduly taxing the resources of ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... performance system, has partnered with O2X , an active lifestyle company that ... on improving the health of firefighters, police offers, first responders, military officers and ...
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California Medical ... Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended annual ... healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, share ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home ... of Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business ... our agency and our ability to provide quality care to the community,” said Tammara ...
(Date:4/21/2017)... AUGUSTA, GA (PRWEB) , ... April 21, 2017 , ... ... Festival in Augusta, Georgia. , This festival offers entertainment for everyone — from ... Sacred Heart Garden Festival is a very high quality event held in a grand ...
Breaking Medicine News(10 mins):